Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
Both of these businesses are finding traction in a pair of major markets.
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects....
This mid-cap biopharma may one day be a titan of the industry.
There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...
These stocks are both experts in their respective fields.
These pharmaceutical companies are top-notch dividend growth stocks for the future.
This is a stock you shouldn't hesitate to buy on the dip.